The National Human Genome Research Institute (NHGRI), an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive commercialization patent license to practice the inventions embodied in the Patent Applications listed in the Supplementary Information section of this notice License to Selecta Biosciences (``Selecta'') located in Watertown, Massachusetts.
Document
Prospective Grant of Exclusive License: Development, Manufacture and Commercialization of Gene Therapy Products for Human Gene Therapy Use To Treat and/or Prevent Methylmalonic Acidemia (MMA)
The National Human Genome Research Institute (NHGRI), an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
82 FR 132
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Prospective Grant of Exclusive License: Development, Manufacture and Commercialization of Gene Therapy Products for Human Gene Therapy Use To Treat and/or Prevent Methylmalonic Acidemia (MMA),” thefederalregister.org (January 3, 2017), https://thefederalregister.org/documents/2016-31834/prospective-grant-of-exclusive-license-development-manufacture-and-commercialization-of-gene-therapy-products-for-human-.